Mesa Laboratories Inc. 2026年季度报告

FORM 10-Q ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIESEXCHANGE ACT OF 1934 Securities registered pursuant to Section12(b) of the Act: Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submittedpursuant to Rule 405 of Regulation S-T (Section 232.405 of this chapter) during the preceding 12 months (or for such shorter Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smallerreporting company or an emerging growth company. See definitions of “large accelerated filer,” “accelerated filer,” “smaller If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period forcomplying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).Yes☐No☒ Indicate the number of shares outstanding of each of the Issuer’s classes of common stock, as of the latest practicable date: There were 5,524,813shares of the Issuer’s common stock, no par value, outstanding as of January31, 2026. Table of Contents PART I. FINANCIAL INFORMATION Exhibit 31.1 Certifications Pursuant to Rule 13a-14(a)Exhibit 31.2 Certifications Pursuant to Rule 13a-14(a)Exhibit 32.1 Certifications Pursuant to Rule 13a-14(b) and 18 U.S.C Section 1350Exhibit 32.2 Certifications Pursuant to Rule 13a-14(b) and 18 U.S.C Section 1350 Mesa Laboratories, Inc.Condensed Consolidated Balance Sheets(unaudited)(in thousands, except share amounts) Mesa Laboratories, Inc.Condensed Consolidated Statements of Operations Mesa Laboratories, Inc.Condensed Consolidated Statements of Cash Flows Mesa Laboratories, Inc.Notes to Condensed Consolidated Financial Statements(unaudited) Note 1. Description of Business and Summary of Significant Accounting Policies Description of Business In this quarterly report on Form 10-Q, Mesa Laboratories, Inc., a Colorado corporation, together with its subsidiaries, iscollectively referred to as “we,” “us,” “our,” the “Company,” or “Mesa.” We are a global leader in the design and manufacture of life sciences tools and critical quality control solutions for regulatedapplications in the pharmaceutical, healthcareand medical device industries. We offer products and services to help our customersensure product integrity, increase patient and worker safety, and improve the quality of life throughout the world. We have As of December 31, 2025, we managed our operations in four reportable segments, or divisions: ●Sterilization and Disinfection Control- manufactures and sells biological, chemical and cleaning indicators used to assessthe effectiveness of sterilization, decontamination, disinfection and cleaning processes in the pharmaceutical, medical ●Biopharmaceutical Development- develops, manufactures, sells and services automated systems for protein analysis(immunoassays) and peptide synthesis solutions. Immunoassays and peptide synthesis solutions accelerate the discovery, ●Calibration Solutions- develops, manufactures,sells and services quality control products using principles of advancedmetrology to enable customers tomeasure and calibrate critical parameters in applications such as renal care, ●Clinical Genomics-develops, manufactures and sells highly sensitive high-throughput genetic analysis tools and relatedconsumables and services that enable clinical research labs and contract research organizations to performgenomic testingfor a broad range of research applications in several therapeutic areas, such as screenings for hereditary diseases, Basis of Presentation The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance withthe rules andregulations of the Securities and Exchange Commission and in accordance with accounting principles generally accepted in theUnited States (“U.S. GAAP”) for interim financial information. In the opinion of management, such unaudited informationincludes all adjustments, consisting of normal recurring adjustments, necessary for thefair statement of our financial position andresults of operations. The results of operations for interim periods are not necessarily indicative of results that may be achieved forthe entire year.The year-end Condensed Consolidated Balance Sheet data was derived from audited financial statementsbut does Our fiscal year ends on March31. References in thisreport to a particular “year” or “quarter”refer to our fiscal year or fiscalquarters, respectively. Unless otherwise indicated, amounts shown in this report are in thousands. Risks and Uncertainties The preparation of financial statements requires the use of estimates and assumptions that affect reported amounts of assets andliabilities at the reporting date and revenues and expenses